Pretax income is the income that a company earns before paying income taxes. Genocea Biosciences's pretax income for the
three
months ended in Mar. 2022 was $-15.98 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2022 was $-37.19 Mil.
Genocea Biosciences's pretax margin was -5,917.78%.
During the past 11 years, Genocea Biosciences's highest Pretax Margin was -676.13%. The lowest was -21094.89%. And the median was -3216.63%.
Genocea Biosciences Pre-Tax Income Historical Data
The historical data trend for Genocea Biosciences's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Genocea Biosciences's Pre-Tax Income
For the Biotechnology subindustry, Genocea Biosciences's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genocea Biosciences's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genocea Biosciences's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Genocea Biosciences's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-37.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genocea Biosciences (OTCPK:GGNNQ) Pre-Tax Income Explanation
Genocea Biosciences's Pretax Margin for the quarter that ended in Mar. 2022 is calculated as
During the past 11 years, Genocea Biosciences's highest Pretax Margin was -676.13%. The lowest was -21094.89%. And the median was -3216.63%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genocea Biosciences Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Genocea Biosciences's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Genocea Biosciences Inc is a USA-based biopharmaceutical company discovering and developing novel cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens , that drive pro-tumor immune responses.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GGNNQ has been successfully added to your 